Related Experiment Video
Updated: Aug 14, 2026

Investigation of Genetic Dependencies Using CRISPR-Cas9-based Competition Assays
Published on: January 7, 2019
ELAVL1-KO Affects Steroid Synthesis in ACC Cell Line NCI-H295R and Reduces Colony-Forming Abilities
Max Brandau1, Vanessa Kirsch1, Dmitry Chernyakov1
1Klinik für Innere Medizin IV, Landeszentrum für Zell-und Gentherapie, Universitätsklinikum Halle (Saale), 06120 Halle (Saale), Germany.
Abstract:
Adrenocortical carcinoma (ACC) is a rare malignancy of the adrenal gland for which no curative treatment options exist in advanced stages. Analyzing the ACC cohort of The Cancer Genome Atlas, we identified that expression of the mRNA-stabilizing protein Embryonic-Lethal-Abnormal-Vision-Like RNA-Binding Protein 1 (ELAVL1) was negatively associated with patient survival. To investigate the functional role in ACC, we generated a CRISPR/Cas9-mediated ELAVL1 knockout (KO) in the ACC cell lines NCI-H295R and HAC15 and performed Next-Generation RNA Sequencing (NGS) to characterize transcriptomic changes. In NCI-H295R, NGS analysis revealed 3468 upregulated genes and 3458 downregulated genes in ELAVL1-deficient cells compared with controls. Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis identified significant enrichment of aldosterone biosynthesis-related genes and enriched downregulation of genes associated in with "pathways in cancer." Functionally, ELAVL1-KO cells exhibited impaired colony-forming ability, indicating reduced proliferative or clonogenic potential. Steroid profiling of cell culture supernatants further demonstrated increased aldosterone synthesis and decreased cortisol and androgen production in the KO cells, consistent with the observed transcriptional changes. Given that hypercortisolism is an established negative prognostic factor in ACC, these data suggest that ELAVL1 may represent a potential therapeutic target worth further investigation for modulating steroidogenesis in ACC patients.
Insights
Embryonic-Lethal-Abnormal-Vision-Like RNA-Binding Protein 1 (ELAVL1) impacts adrenocortical carcinoma (ACC) progression. ELAVL1 depletion reduces cancer cell proliferation and alters steroidogenesis, suggesting ELAVL1 as a potential therapeutic target for ACC.
Area of Science:
- Oncology
- Molecular Biology
- Endocrinology
Background:
- Adrenocortical carcinoma (ACC) is a rare adrenal gland cancer with limited treatment options for advanced stages.
- Embryonic-Lethal-Abnormal-Vision-Like RNA-Binding Protein 1 (ELAVL1) expression is linked to poorer patient survival in ACC.
- Understanding ELAVL1's functional role is crucial for developing novel ACC therapies.
Purpose of the Study:
- To investigate the functional role of ELAVL1 in adrenocortical carcinoma.
- To characterize the transcriptomic and steroidogenic consequences of ELAVL1 deficiency in ACC cells.
Main Methods:
- CRISPR/Cas9 gene editing was used to create ELAVL1 knockout (KO) ACC cell lines (NCI-H295R, HAC15).
- Next-Generation RNA Sequencing (NGS) analyzed transcriptomic alterations in ELAVL1-deficient cells.
- Steroid profiling assessed changes in hormone synthesis in KO cells.
Main Results:
- ELAVL1 depletion significantly altered gene expression, upregulating 3468 and downregulating 3458 genes in NCI-H295R cells.
- KEGG pathway analysis revealed enrichment in aldosterone biosynthesis and downregulation in "pathways in cancer."
- ELAVL1-KO cells showed reduced colony formation, increased aldosterone synthesis, and decreased cortisol and androgen production.
Conclusions:
- ELAVL1 deficiency impairs ACC cell proliferation and alters steroid hormone production.
- ELAVL1 plays a significant role in ACC pathogenesis and steroidogenesis.
- ELAVL1 inhibition presents a potential therapeutic strategy for adrenocortical carcinoma.